Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Castle Biosciences Inc.

< Previous 1 2 Next >
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports First Quarter 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Announces Updates to its Board of Directors
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas
From Castle Biosciences Inc.
Via Business Wire
Tickers CSTL
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.